Electronic effect‐dependent intramolecular non‐covalent interactions on the activity of 4,4‐dimethylimidazolidin‐2‐one pharmacophore‐based androgen receptor antagonists-Reference-Cited by-同舟云学术

Electronic effect‐dependent intramolecular non‐covalent interactions on the activity of 4,4‐dimethylimidazolidin‐2‐one pharmacophore‐based androgen receptor antagonists

Published:2022-10-17 Issue:3 Volume:101 Page:614-625
ISSN:1747-0277
Container-title:Chemical Biology & Drug Design
language:en
Short-container-title:Chem Biol Drug Des

Author:

Yaragani Muralikrishna¹,Yadlapalli Prasad²,Raghavan Sriram³,Giridhar Thota⁴,Mandava Venkata Basaveswara Rao⁵,Singh Ravindra Vikram⁴,Kottapalli Rajasekhara Prasad¹,Chinnusamy Saravanan⁶

Affiliation:

1. Department of Chemistry Koneru Lakshmaiah Education Foundation Guntur Andhra Pradesh India

2. GVK Biosciences Pvt. Ltd Hyderabad Telangana India

3. CAS in Crystallography and Biophysics University of Madras, Guindy Campus Chennai Tamil Nadu India

4. Sigma‐Aldrich Chemicals Pvt. Ltd Bangalure Karnataka India

5. Department of Chemistry Krishna University Krishna Andhra Pradesh India

6. Center for Advanced Organic Materials (Sona‐AROMA), Department of Chemistry Sona College of Technology Salem Tamil Nadu India

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cbdd.14151

Reference40 articles.

1. Use of Intramolecular 1,5-Sulfur–Oxygen and 1,5-Sulfur–Halogen Interactions in the Design of N-Methyl-5-aryl-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1,3,4-thiadiazol-2-amine SMN2 Splicing Modulators

2. Structural basis for antagonism and resistance of bicalutamide in prostate cancer

3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

4. Role of prostate-specific antigen as a predictor of outcome in prostate cancer

5. Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity